Checkpoint Therapeutics, Inc, an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in the phase 1/2 clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and CK-301, a programmed death ligand-1 (PD-L1), which is in phase I clinical trial in patients with selected recurrent or metastatic cancers.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-652-4500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.51 million
Profitability
Miscellaneous
Employees7
Next Earnings Date11/1/2019 (Estimated)
OptionableNot Optionable
Checkpoint Therapeutics (NASDAQ:CKPT) Frequently Asked Questions
What is Checkpoint Therapeutics' stock symbol?
Checkpoint Therapeutics trades on the NASDAQ under the ticker symbol "CKPT."
How were Checkpoint Therapeutics' earnings last quarter?
Checkpoint Therapeutics Inc (NASDAQ:CKPT) issued its earnings results on Thursday, August, 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.16) by $0.01. The business earned $1.05 million during the quarter, compared to analyst estimates of $0.96 million. Checkpoint Therapeutics had a negative return on equity of 263.14% and a negative net margin of 712.89%. View Checkpoint Therapeutics' Earnings History.
When is Checkpoint Therapeutics' next earnings date?
What price target have analysts set for CKPT?
2 equities research analysts have issued 12-month target prices for Checkpoint Therapeutics' shares. Their predictions range from $15.00 to $15.00. On average, they anticipate Checkpoint Therapeutics' stock price to reach $15.00 in the next year. This suggests a possible upside of 403.4% from the stock's current price. View Analyst Price Targets for Checkpoint Therapeutics.
What is the consensus analysts' recommendation for Checkpoint Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Checkpoint Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Checkpoint Therapeutics.
What are Wall Street analysts saying about Checkpoint Therapeutics stock?
Here are some recent quotes from research analysts about Checkpoint Therapeutics stock:
- 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $15 price target. Our valuation is based on our clinical net present value (NPV) model, which is currently driven by the company’s two lead assets, cosibelimab and CK-101. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway." (8/9/2019)
- 2. According to Zacks Investment Research, "Checkpoint Therapeutics, Inc. is a clinical stage, immuno oncology biopharmaceutical. It focused on the acquisition, development and commercialization of non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics, Inc. is headquartered in New York City. " (3/20/2019)
Has Checkpoint Therapeutics been receiving favorable news coverage?
News headlines about CKPT stock have been trending positive this week, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Checkpoint Therapeutics earned a news impact score of 2.5 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an effect on the stock's share price in the next several days. View News Stories for Checkpoint Therapeutics.
Are investors shorting Checkpoint Therapeutics?
Checkpoint Therapeutics saw a decline in short interest in the month of July. As of July 31st, there was short interest totalling 541,000 shares, a decline of 7.6% from the June 30th total of 585,500 shares. Based on an average daily trading volume, of 130,000 shares, the days-to-cover ratio is currently 4.2 days. Approximately 2.7% of the company's stock are short sold. View Checkpoint Therapeutics' Current Options Chain.
Who are some of Checkpoint Therapeutics' key competitors?
Some companies that are related to Checkpoint Therapeutics include Dova Pharmaceuticals (DOVA), Urogen Pharma (URGN), Puma Biotechnology (PBYI), Crinetics Pharmaceuticals (CRNX), Magenta Therapeutics (MGTA), Evolus (EOLS), Organogenesis (ORGO), Flexion Therapeutics (FLXN), BioSpecifics Technologies (BSTC), Obseva (OBSV), CytomX Therapeutics (CTMX), Merus (MRUS), ChemoCentryx (CCXI), Provention Bio (PRVB) and CymaBay Therapeutics (CBAY).
What other stocks do shareholders of Checkpoint Therapeutics own?
Who are Checkpoint Therapeutics' key executives?
Checkpoint Therapeutics' management team includes the folowing people:
- Mr. James F. Oliviero III, CFA, CEO, Pres & Director (Age 43)
- Mr. William Garrett Gray, VP of Fin. & Accounting, Principal Financial Officer and Corp. Sec. (Age 32)
Who are Checkpoint Therapeutics' major shareholders?
Checkpoint Therapeutics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.77%), Vanguard Group Inc. (3.36%), Northern Trust Corp (0.17%), Bank of New York Mellon Corp (0.16%), Royal Bank of Canada (0.14%) and Charles Schwab Investment Management Inc. (0.13%). View Institutional Ownership Trends for Checkpoint Therapeutics.
Which institutional investors are selling Checkpoint Therapeutics stock?
Which institutional investors are buying Checkpoint Therapeutics stock?
CKPT stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Vanguard Group Inc., Bank of New York Mellon Corp, Susquehanna International Group LLP, Jane Street Group LLC, Charles Schwab Investment Management Inc., Acadian Asset Management LLC and Northern Trust Corp. View Insider Buying and Selling for Checkpoint Therapeutics.
How do I buy shares of Checkpoint Therapeutics?
Shares of CKPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Checkpoint Therapeutics' stock price today?
One share of CKPT stock can currently be purchased for approximately $2.98.
How big of a company is Checkpoint Therapeutics?
Checkpoint Therapeutics has a market capitalization of $113.21 million and generates $3.51 million in revenue each year. The company earns $-36,370,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Checkpoint Therapeutics employs 7 workers across the globe.View Additional Information About Checkpoint Therapeutics.
What is Checkpoint Therapeutics' official website?
How can I contact Checkpoint Therapeutics?
Checkpoint Therapeutics' mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The company can be reached via phone at 781-652-4500 or via email at [email protected]
MarketBeat Community Rating for Checkpoint Therapeutics (NASDAQ CKPT)
MarketBeat's community ratings are surveys of what our community members think about Checkpoint Therapeutics and other stocks. Vote "Outperform" if you believe CKPT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CKPT will underperform the S&P 500 over the long term. You may vote once every thirty days.
